ENDRA Life Sciences NAFLD Assessment 2020 Investor Presentation

ENDRA Life Sciences presents its TAEUS™ enhanced imaging platform targeting NAFLD and NASH, which affect approximately 1 billion people globally. The company focuses on regulatory approval and commercialization in 2020, with an $18 billion market opportunity and a capital-efficient operating model leveraging partnerships with leading healthcare and AI organizations.